Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE

William P Kennedy, Romeo Maciuca, Kristen Wolslegel, Wei Tew, Alexander R Abbas, Christina Chaivorapol, Alyssa Morimoto, Jacqueline M McBride, Paul Brunetta, Bruce C Richardson, John C Davis Jr, Timothy W Behrens, Michael J Townsend

ABSTRACT

Objectives: The interferon (IFN) signature (IS) in patients with systemic lupus erythematosus (SLE) includes over 100 genes induced by type I IFN pathway activation. We developed a method to quantify the IS using three genes—the IS metric (ISM)—and characterised the clinical characteristics of patients with SLE with different ISM status from multiple clinical trials.

Methods: Blood microarray expression data from a training cohort of patients with SLE confirmed the presence of the IS and identified surrogate genes. We assayed these genes in a quantitative PCR (qPCR) assay, yielding an ISM from the IS. The association of ISM status with clinical disease characteristics was assessed in patients with extrarenal lupus and lupus nephritis from four clinical trials.

Results: Three genes, HERC5, EPSTI and CMPK2, correlated well with the IS (r>0.96), and composed the ISM qPCR assay. Using the 95th centile for healthy control data, patients with SLE from different studies were classified into two ISM subsets—ISM-High and ISM-Low—that are longitudinally stable over 36 weeks. Significant associations were identified between ISM-High status and higher titres of anti-dsDNA antibodies, presence of anti extractable nuclear antigen autoantibodies, elevated serum B cell activating factor of the tumour necrosis factor family (BAFF) levels, and hypocomplementaemia. However, measures of overall clinical disease activity were similar for ISM-High and ISM-Low groups.

Conclusions: The ISM is an IS biomarker that divides patients with SLE into two subpopulations—ISM-High and ISM-Low—with differing serological manifestations. The ISM does not distinguish between high and low disease activity, but may have utility in identifying patients more likely to respond to treatment(s) targeting IFN-α.

Clinicaltrials.gov registration number: NCT00962832.

KEY MESSAGES

- A three-gene surrogate (interferon signature metric, ISM) for the interferon signature in patients with systemic lupus erythematosus (SLE) has a distinct bimodal profile that is similar across different interventional clinical SLE studies.
- The ISM profile distinguishes patients with SLE on serological characteristics but not on clinical phenotype.
- Patients with an ISM-High status have elevated anti-dsDNA and ENA autoantibodies, hypocomplementaemia, and elevated serum BAFF levels.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology. It is characterised by the presence of pathogenic autoantibodies to nuclear antigens, elevated immune complexes (ICs), and immunological abnormalities, including lymphopenia, elevated immunoglobulin and autoantibody levels, complement activation, and abnormal activation of the innate and adaptive immune system, and often leads to multisystem organ damage.1–3

Development of novel therapies to manage SLE has been hampered by several challenges, including poorly understood pathogenesis, the heterogeneity of disease activity across and within patient populations, and difficulties conducting interventional studies.4, 5 One approach for development of successful therapies may follow from efforts to identify useful biomarkers that can classify patients with SLE into more homogeneous subtypes for use in clinical trials and clinical practice.
Activation of the type I interferon (IFN) pathway has been implicated in the initiation of SLE and perpetuation of the resultant clinical disease. Elevated levels of IFN-α are associated with disease activity, flares and tissue injury, especially of the skin, kidney and nervous system. Genetic association studies show polymorphisms in SLE associated with kinase cascade signalling genes for type I IFNs and in IFN-regulated genes (IRGs). Further, gene expression profiling studies have identified an IFN signature (IS), or a prominent upregulation of mRNA transcripts encoded by IRGs, in a subset of patients with SLE and other autoimmune diseases. It has been hypothesised that dysregulation of the type I IFN signalling pathway could override immune tolerance mechanisms, leading to formation of autoreactive antibodies. Therefore, blockade of the type I IFN pathway, especially of IFN-α, may be a strategy for selective immunosuppression in patients with SLE with elevated IS expression whose pathophysiology of disease is driven by IFN dysregulation.

We previously described an application of a quantitative reverse transcription PCR (qPCR) biomarker assay to accurately measure the IFN signature in patients with SLE using a three-gene surrogate called the IS metric (ISM). Here, we describe the development of the ISM assay, its validation in multiple SLE clinical trial cohorts, and characterise the clinical and serological features associated with the ISM-Low and ISM-High subsets of patients with SLE.

PATIENTS AND METHODS

Cohorts of patients with SLE

All patients met the American College of Rheumatology criteria for SLE. This trial is registered (NCT00962832) on the ClinicalTrials.gov website. For purposes of executing clinical trials with different end points, patients with SLE are characterised predominantly as patients with extrarenal lupus (ERL) or as patients with lupus nephritis (LN). The following cohorts were evaluated: 61 patients with ERL in the University of Michigan observational cohort, 60 patients with mild ERL enrolled in the rontalizumab Phase I trial, 135 patients with moderate-severe ERL in the EXPLORER rituximab trial, 80 patients with moderate-severe LN in the LUNAR rituximab trial, and 238 patients with moderate-severe ERL in the ROSE rontalizumab (anti-IFN-α monoclonal antibody) trial. Further descriptions are in the online supplementary methods. Healthy control subjects (n=85) were recruited by the Genentech blood donation programme for research use of blood samples, and were age matched and gender matched to the lupus trial patients.

Blood RNA extraction and microarray analysis

Detailed methodology is presented in the online supplementary methods. RNA from SLE cohorts was isolated from peripheral blood mononuclear cells (PBMCs) and/or PAXgene whole blood samples. Genome-wide expression data were obtained using Affymetrix Human Genome U133 Plus V2.0 expression microarrays, and data analysis was performed using Bioconductor R packages. Microarray ISM scores were derived from the scaled geometric mean across included genes for each sample subjected to exponentiation by 2. Microarray data have been submitted to the gene expression omnibus (GEO) repository under the accession number GSE50772.

Development of the ISM PCR assay

The qPCR assays were developed with primers and fluorescent dye-labelled probes for IRGs and housekeeping genes and run on the Agilent Mx2500P and the Applied Biosystems 7900HT platforms. The three-gene ISM score was calculated using expression values from the gene complementary DNAs (cDNAs) CMPK2, EPST11, HERC5, and normalised using the housekeeping gene TFRC. The ISM score was calculated from the mean of the CMPK2, EPST11 and HERC5 cycle threshold (Ct)—TFRC G (ΔCt) values and multiplied by −1 to give the correct directionality of relative log2-scaled expression. Baseline ROSE trial samples were assessed using this assay developed on the Cobas 4800 platform (Roche Molecular Systems) as a prototype diagnostic test.

Measurement of serum analytes

Levels of serum creatine were determined with Roche Modular Analysers using a modified Jaffe reaction. Levels of complement C3 and C4 components were determined using standard immunonephelometry methods. Anti-dsDNA, anti-SSA/Ro, anti-SSB/La, anti-ribonucleoprotein (RNP) and anti-Sm were measured using a bead-based immunoassay (AtheNA Multi-Lyte antinuclear antibodies Test System). Serum concentrations of B cell-activating factor of the tumour necrosis factor family (BAFF) were determined by an ELISA using monoclonal antibodies developed at Genentech, with a standard curve using recombinant human BAFF. Serum bioactivity was determined using U-937 cells stably transfected with the pGL4.14 vector containing a 1.5 kb fragment of the myxovirus influenza resistance 1 promoter, where samples were added to reporter cells for 24 h alongside a standard curve of recombinant IFN-α for quantification. Luciferase levels were measured by Luminoimeter instrumentation.

Statistical analysis

Demographics and key baseline patient characteristics were compared using descriptive statistics, that is, differences between ISM-Low and ISM-High patients in mean values. Statistical testing was performed using the Wilcoxon rank-sum test or the Fisher’s exact test as appropriate. No adjustments for multiple comparisons were performed for individual statistical tests. The longitudinal stability of the ISM was evaluated in patients who received placebo, and data were used to establish the probability of reproducibility (P_rep) of ISM-Low or ISM-High categorisation (range 0–100%) when samples
RESULTS
Derivation of the ISM biomarker
Using unsupervised hierarchical clustering of samples and probe sets derived from expression microarray analysis of PBMCs in the University of Michigan SLE cohort, we observed that patients with SLE (n=61) and control patients (n=20) had distinct gene expression at the genome-wide level (see online supplementary figure S1). A cluster of 128 genes had high representation of IRGs, relating to the previously described IS, which was elevated in ~50% of patients with SLE (figure 1A and see online supplementary table S1). Composites of only a few genes could yield scores that were highly correlated to the score calculated from the 128-gene cluster (figure 1B). Quantitative PCR of whole blood RNA samples obtained from the same patients in this training cohort for a three-gene combination (HERC5, EPSTI1 and TYKI/CMPK2) was a robust surrogate for the original 128-gene IS observed in the matching PBMC RNA samples (figure 1C)—defined hereafter as the ISM. Therefore, the magnitude of the microarray IS that was originally identified by microarray analysis of PBMC RNA samples could be measured accurately using a three-gene qPCR assay of corresponding whole blood RNA samples.

ISM profile in healthy controls and different lupus populations
The ISM scores were generated from whole blood RNA samples from a cohort of 85 additional healthy control subjects and pretreatment samples from patients enrolled in the Phase I trial of rontalizumab (anti-IFN-α) in mild SLE, the EXPLORER trial of rituximab (anti-CD20) in moderate-severe ERL and from the LUNAR trial of rituximab in moderate-severe LN (see Methods). Consistent with the Michigan SLE cohort data, a subset of patients with ERL and LN had significantly elevated ISM scores while other patients had ISM scores that overlapped those of healthy control subjects (figure 2A). The lupus populations exhibited a strong bimodal ISM separation, indicating two distinct patient subsets. A threshold for the ISM score at the 95th centile of the healthy subject ISM scores was calculated to be at an ISM score of 1, separating patients with lupus into ISM-Low and ISM-High subsets. Compared with the ISM-Low subjects, whose median ISM score of ~0.8 overlapped with the control population, the ISM-High subset had a median ISM score ≥2.3, corresponding to an eightfold higher expression of the ISM genes (figure 2B) in ISM-High versus ISM-Low subsets. The bimodal distribution and elevation of ISM was consistent in patients from the ROSE Phase II trial (figure 2C), with the median for ISM-High patients indicating sevenfold higher IS expression than in ISM-Low patients (figure 2D).

Baseline demographics by ISM across four SLE populations
In a mild ERL population enrolled in a Phase I study,16 the ratio of ISM-Low to ISM-High patients was approximately 1:1. In contrast, in a moderate-to-severe ERL population (EXPLORER) and an LN population (LUNAR), 70–75% of patients were ISM-High (table 1) at baseline. Furthermore, 76% of patients in the ROSE moderate-to-severe SLE trial were designated ISM-High. Gender did not differ between ISM-Low and ISM-High patients in any of the cohorts. However, in the Phase I EXPLORER and LUNAR trials, the ISM-Low patients tended to be older than the ISM-High patients—a trend that was also seen in the ROSE trial—with a 5-year mean difference between the groups. While there was a trend for increased representation of the African-American ethnicity in ISM-Low versus ISM-High subsets of the ERL cohorts, the prevalence of such patients in the studies was low and the trend was not observed in the LUNAR trial.

Clinical disease activity by ISM across four lupus cohorts
Within each SLE trial, global disease activity did not differ between ISM-Low and ISM-High patient subsets as defined by the British Isles Lupus Assessment Group (BILAG) activity index, Safety of Estrogen in Lupus Erythematosus-National Assessment (SELENA)—Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, or Physician Global Assessment (table 1). Within the context of enrolment criteria based on SELENA-SLEDAI or BILAG measures and/or renal impairment, disease activity at baseline did not differ between ISM-Low and ISM-High patients with SLE. Furthermore, mucocutaneous involvement did not differ between the two ISM subsets across the four studies. There was a consistent trend for increased musculoskeletal involvement in the ISM-Low versus ISM-High patients, but this was not statistically significant.

In addition, data was collected in the ROSE trial for Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) as well as for the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system of fatigue. Of note, we observed a significant association between ISM-High status and the CLASI damage score; ISM-High (n=180) mean 2.1, SD 5.7, versus ISM-Low (n=58) mean 0.3, SD 1.0, Wilcoxon p=0.0209. However, we did not see a significant association between ISM status and the CLASI activity score; ISM-High mean 5.8 (SD 6.5) versus ISM-Low mean 7.0.
Further, there was a trend observed for elevated FACIT fatigue scores in ISM-High patients; ISM-High mean 27.5 (SD 1.43) versus ISM-Low mean 24.3 (SD 13.7), p=0.074.

Increased serological manifestations in ISM-High patients with lupus

In the ERL trials, the ISM-High subset had decreased levels of C3 and C4 complement components relative to the ISM-Low subset, and these differences were consistent in the ROSE trial (table 2). In contrast, C3 and C4 levels did not differ in the ISM subpopulations in the LUNAR LN trial. ISM-High status was associated with elevation of anti-dsDNA titres (figure 3A) and increased incidence of positive extractable nuclear antigen antibody status (figure 3B) as compared with ISM-Low patients with ERL. Levels of these autoantibodies did not significantly differ between ISM-High and ISM-Low patients with LN. Serum BAFF levels were elevated in the ISM-High versus ISM-Low subsets in patients with ERL and LN (figure 3C, table 2). In patients with ERL, type I IFN serum bioactivity was also elevated in the ISM-High subset.
patients relative to ISM-Low patients (figure 3D); this was not assessed in patients with LN. We further assessed C reactive protein (CRP) levels between ISM-High and ISM-Low patients, and noted that while CRP levels were elevated in ISM-High patients in the ROSE trial; ISM-High mean 0.81 mg/dL (SD 1.43) versus ISM-Low 0.42 mg/dL (SD 0.6), p=0.019, there were no significant elevations in CRP levels between ISM-High patients versus ISM-Low patients across the other trials (table 1). It was further noteworthy that across the four trials, total leucocyte counts and lymphocyte, neutrophil, monocyte and eosinophil counts were consistently lower in ISM-High patients (see online supplementary table S2).

Multivariate analysis of the ISM score
Absolute counts of CD4, anti extractable nuclear antigen status, levels of BAFF and anti-dsDNA, and SLE disease duration were independently associated with the ISM score (see online supplementary table S3). Longer disease duration was the only non-serological component of the model associated with lower ISM scores. A statistically non-significant trend for an association between the ISM score and age at baseline was noted.

Determination of longitudinal stability of the ISM
Patients receiving placebo (n=61) had a 94% probability of being consistently categorised in the same ISM subset throughout the 36-week period (see online supplementary table S4). Patients with an ISM score closer to the cut-off of 1 (>−0.5 to ≤2, n=17) had a lower likelihood (81% to 85%) of maintaining their ISM status, while patients with ISM scores further from the cut-off (≤−0.5 or >2, n=44) had a higher (97% to 100%)
| Parameter                      | Phase I rontalizumab trial—mild SLE                  | EXPLORER trial—moderate-to-severe SLE                  |
|-------------------------------|-----------------------------------------------------|------------------------------------------------------|
|                               | ISM-Low (n=32) ISM-High (n=28) Total (N=60) | ISM-Low (n=40) ISM-High (n=95) Total (N=135) |
| Age (years), mean (SD)        | 48.2 (9.7) 46.5 (10.5) 47.4 (10.0) | 42.8 (11.4) 38.8 (10.9) 39.9 (11.2) |
| SLE duration (years), mean (SD)| 7.5 (5.6) 10.4 (7.1) 8.8 (6.4) | 8.2 (7.9) 9.2 (8.0) 8.9 (7.7) |
| Female, %                     | 97 93 95 | 100 92 94 |
| Race/ethnicity, %             |                                      |                                                      |
| Black                         | 12.5 42.9 26.7 | 12.5 29.5 24.4 |
| Hispanic*                     | 0 7.1 3.3 | 12.5 16.8 15.6 |
| White                         | 87.5 50 70 | 72.5 49.5 56.3 |
| Other                         | 0 0 0 | 2.5 4.2 3.7 |
| BILAG index global, mean (SD) | N/A N/A N/A | 13.1 (4.7) 15.2 (5.2) 14.5 (5.2) |
| SELENA-SLEDAI, mean (SD)      | 4.1 (2.6) 2.9 (2.7) 3.6 (2.7) | 9.3 (6.2) 9.2 (8.0) 10.9 (6.4) |
| PGA, mean (SD)                | 25.5 (15.1) 17.3 (17.6) 21.7 (16.7) | 50.5 (20.4) 55.7 (15.3) 54.1 (17.0) |
| Musculoskeletal involvement, % | 37.5 28.6 33.3 | 92.5 80.0 83.7 |
| Mucocutaneous involvement, %  | 84.4 64.3 75.0 | 60.0 81.1 74.8 |
| Proteinuria (>0.5 g), %       | 0.0 0.0 0.0 | 0.0 2.1 1.5 |
| Serum creatine (mg/dL), mean (SD) | 0.8 (0.1) 0.9 (0.2) 0.8 (0.2) | 0.8 (0.2) 0.7 (0.2) 0.7 (0.2) |
| Serum C reactive protein (mg/dL), mean (SD) | 0.59 (0.71) 0.34 (0.35) 0.47 (0.58) | 0.89 (1.33) 0.79 (1.44) 0.81 (1.41) |

| Parameter                      | LUNAR Trial‡—LN                  | Phase II Rontalizumab ROSE Trial—Moderate-to-Severe SLE |
|-------------------------------|---------------------------------|--------------------------------------------------------|
|                               | ISM-Low (n=21) ISM-High (n=59) Total (N=80) | ISM-Low (n=58) ISM-High (n=180) Total (N=238) |
| Age (years), mean (SD)        | 31.4 (10.9) 30.0 (9.1) 30.4 (9.6) | 42.6 (11.8) 37.6 (10.9) 38.8 (11.3) |
| SLE duration (years), mean (SD)| 6.2 (6.7) 4.7 (4.6) 5.1 (5.2) | 7.2 (7.7) 6.2 (5.8) 6.5 (6.3) |
| Female, %                     | 81 93 90 | 97 93 94 |
| Race/ethnicity, %             |                                      |                                                      |
| Black                         | 19.1 20.3 20 | 8.6 16.1 14.3 |
| Hispanic*                     | 57.1 40.7 45 | 25.9 36.1 33.6 |
| White                         | 23.8 37.3 33.8 | 55.2 43.3 46.2 |
| Other                         | 0 1.7 1.3 | 10.3 4.4 5.9 |
| BILAG index global, mean (SD) | 15.8 (5.8) 14.3 (6.5) 14.7 (6.3) | 11.9 (4.9) 11.0 (4.6) 11.2 (4.7) |
| SELENA-SLEDAI, mean (SD)      | N/A N/A N/A | 9.2 (2.6) 10.0 (3.5) 9.8 (3.3) |
| PGA, mean (SD)                | 51.6 (24.2) 49.4 (21.2) 50.0 (21.9) | 52.1 (17.2) 57.5 (16.0) 56.2 (16.4) |
| Musculoskeletal involvement, % | 28.6 18.6 21.3 | 98.3 95.6 96.2 |
| Mucocutaneous involvement, %  | 38.1 32.2 33.8 | 77.6 75.6 76.1 |
| Proteinuria (>0.5 g), %       | 100 94.9 96.3 | 0.0 1.7 1.3 |
| Serum creatine (mg/dL), mean (SD) | 1.0 (0.4) 1.0 (0.6) 1.0 (0.5) | 0.8 (0.2) 0.8 (0.2) 0.8 (0.2) |
| Serum C reactive protein (mg/dL), mean (SD) | 0.4 (0.56) 0.63 (1.08) 0.57 (0.97) | 0.42 (0.6) 0.81 (1.43) 0.71 (1.29) |

*Hispanic defined as a person of self-declared race other than black or white, and self-declared ethnicity Hispanic or Latino.
†BILAG index scores of A, B or present on SELENA-SLEDAI.
‡LUNAR patients missing an ISM score were not included.
§P=0.0042, ISM-Low versus ISM-High.
BILAG, British Isles Lupus Assessment Group; ISM, interferon signature metric; LN, lupus nephritis; N/A, not applicable; PGA, Physician Global Assessment; SELENA, Safety of Estrogen in Lupus Erythematosus-National Assessment; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

Kennedy WP, Maciuca R, Wolslegel K, et al. Lupus Science & Medicine 2015; 2:e000080. doi:10.1136/lupus-2014-000080.
Table 2  Baseline serological characteristics versus ISM status for patients from the Rontalizumab Phase I, rituximab EXPLORER, rituximab LUNAR and rontalizumab Phase II ROSE studies

| Serology parameter | Phase I Study | | | EXPLORER Study | | | ROSE study |
|-------------------|--------------|--------------|---------------|--------------|--------------|---------------|
|                   | ISM-Low (n=32) | ISM-High (n=28) | Total (N=60) | ISM-Low (n=40) | ISM-High (n=95) | Total (N=135) |
| C3 (mg/dL), mean (SD) | 133.5 (29.6) | 120.6 (36.1) | 128.7 (28.1) | 120.6 (36.1) | 92.7 (30.9) | 100.9 (34.9) |
| C4 (mg/dL), mean (SD) | 25.3 (7.7) | 21.2 (9.1) | 23.4 (7.4) | 20.2 (9.1) | 13.6 (7.2) | 15.5 (8.3) |
| Anti-dsDNA (IU/mL), median (IQR) | 12 (12–15) | 15 (12–45) | 12 (12–23) | 12 (12–79) | 71 (29–239) | 44 (13–224) |
| Anti-dsDNA+ (≥30 U/mL), % | 9.4 | 32.1 | 20.0 | 7.5 | 41.5 | 31.3 |
| Anti-ENA+, %* | 6.3 | 60.7 | 31.7 | 10.0 | 59.6 | 44.8 |
| Anti-SSA/Ro52+ (≥120 IU/mL), % | 3.1 | 46.4 | 23.2 | 7.5 | 41.5 | 31.3 |
| Anti-SSB/La+ (≥120 IU/mL), % | 0.0 | 7.1 | 3.3 | 0.0 | 17.0 | 11.9 |
| Anti-RNP+ (≥120 IU/mL), % | 3.1 | 21.4 | 11.7 | 2.5 | 26.6 | 19.4 |
| Anti-Sm+ (≥120 IU/mL), % | 0.0 | 10.7 | 5.0 | 2.5 | 23.4 | 17.2 |
| BAFF† (IU/mL), median (IQR) | 1782(1468–2202) | 2542(1842–3031) | 1975(1589–2862) | 2085(1630–2735) | 3750(2250–6690) | 2870(2000–4960) |

LUNAR study

| Serology parameter | ISM-Low (n=21) | ISM-High (n=59) | Total (N=80) | ISM-Low (n=58) | ISM-High (n=180) | Total (N=238) |
|-------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| C3 (mg/dL), mean (SD) | 77.7 (32.0) | 75.0 (30.2) | 75.7 (30.5) | 121.7 (30.7) | 95.8 (32.6) | 102.1 (34.0) |
| C4 (mg/dL), mean (SD) | 13.7 (8.4) | 14.3 (7.8) | 14.2 (7.9) | 21.4 (8.5) | 14.5 (9.9) | 16.2 (10.0) |
| Anti-dsDNA (IU/mL), median (IQR) | 66 (23–209) | 154 (57–347) | 116 (39–303) | 12 (12–36) | 91 (24–273) | 53 (14–193) |
| Anti-dsDNA+ (≥30 U/mL), % | 57.1 | 84.4 | 77.5 | 34.5 | 70.9 | 62.0 |
| Anti-ENA+, %* | 52.4 | 76.1 | 57.6 | 19.0 | 73.3 | 60.1 |
| Anti-SSA/Ro52+ (≥120 IU/mL), % | 23.8 | 25.4 | 25.0 | 13.8 | 49.4 | 40.8 |
| Anti-SSB/La+ (≥120 IU/mL), % | 9.5 | 8.5 | 8.8 | 5.2 | 16.1 | 13.4 |
| BAFF† (IU/mL), median (IQR) | 1782(1468–2202) | 2542(1842–3031) | 1975(1589–2862) | 2085(1630–2735) | 3750(2250–6690) | 2870(2000–4960) |

ROSE study

| Serology parameter | ISM-Low (n=21) | ISM-High (n=59) | Total (N=80) | ISM-Low (n=58) | ISM-High (n=180) | Total (N=238) |
|-------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| C3 (mg/dL), mean (SD) | 77.7 (32.0) | 75.0 (30.2) | 75.7 (30.5) | 121.7 (30.7) | 95.8 (32.6) | 102.1 (34.0) |
| C4 (mg/dL), mean (SD) | 13.7 (8.4) | 14.3 (7.8) | 14.2 (7.9) | 21.4 (8.5) | 14.5 (9.9) | 16.2 (10.0) |
| Anti-dsDNA (IU/mL), median (IQR) | 66 (23–209) | 154 (57–347) | 116 (39–303) | 12 (12–36) | 91 (24–273) | 53 (14–193) |
| Anti-dsDNA+ (≥30 U/mL), % | 57.1 | 84.4 | 77.5 | 34.5 | 70.9 | 62.0 |
| Anti-ENA+, %* | 52.4 | 76.1 | 57.6 | 19.0 | 73.3 | 60.1 |
| Anti-SSA/Ro52+ (≥120 IU/mL), % | 23.8 | 25.4 | 25.0 | 13.8 | 49.4 | 40.8 |
| Anti-Sm+ (≥120 IU/mL), % | 9.5 | 8.5 | 8.8 | 5.2 | 16.1 | 13.4 |
| BAFF† (IU/mL), median (IQR) | 1782(1468–2202) | 2542(1842–3031) | 1975(1589–2862) | 2085(1630–2735) | 3750(2250–6690) | 2870(2000–4960) |

ENA, extractable nuclear antigen; ISM, interferon signature metric; IU, international unit.

*Positive for two or more autoantigen reactivities of the following: SM+, RNP+, SSA+, SSB+.
†For Phase I, BAFF data are available for n=28 patients (14 ISM-Low, 14 ISM-High).
‡p Value represents ISM-Low versus ISM-High.
likelihood of maintaining their status over the same period of time.

**Decrease in ISM score after dosing of patients with SLE with rontalizumab (anti-IFN-α)**

Treatment with rontalizumab decreased the ISM score relative to placebo during the 24-week treatment period based upon a longitudinal model incorporating all of the time points that demonstrated an intercept that was statistically significantly lower for the rontalizumab groups versus the placebo groups (p<0.01), reflecting a pharmacodynamic response for IFN-α blockade. Application of a mixed-effect model also supported an interaction between baseline ISM score and treatment group (p<0.01), where differences between active treatment and placebo were greater for patients with lower versus higher baseline ISM scores. Despite this pharmacodynamic response, treatment of ISM-High patients with rontalizumab did not decrease the ISM-High scores down to the levels observed in ISM-Low patients (figure 4).

**DISCUSSION**

In this study, we confirmed the presence of an IFN-inducible gene expression signature (IS) in the peripheral blood of patients with SLE and developed a novel and simplified qPCR-based biomarker (ISM) test to quantitate the IS. Importantly, we showed that the magnitude of the ISM biomarker was highly similar between PBMCs and whole blood RNA samples obtained from the same subjects. At baseline, patients...
Figure 4 Decreased interferon (IFN) signature metric (ISM) magnitude after dosing patients with systemic lupus erythematosus (SLE) with rontalizumab (anti-IFN-α). Patients with SLE enrolled in the ROSE trial were dosed over 24 weeks with rontalizumab or placebo (see Methods) and ISM values were determined from pretreatment and post-treatment blood RNA samples collected at monthly frequencies. Blood ISM scores were calculated for pretreatment and post-treatment time points and plotted versus time as mean±SEM for the ISM-High (n=55 for placebo and 120 for rontalizumab) and ISM-Low (n=24 for placebo and 33 for rontalizumab) patient groups as determined at baseline. The ISM scale (y axis) is split between 0 and 2 for clarity, and data from the intravenous (750 mg every 4 weeks) and subcutaneous (300 mg every 2 weeks) dose arms for rontalizumab versus the corresponding placebo arms were pooled for this analysis. Assessment of statistical differences between placebo and rontalizumab groups was based upon a longitudinal model assessing all time points.

with SLE from four different clinical trials consistently fall into one of two subsets—ISM-High and ISM-Low and the bimodal distribution of patients with SLE by the ISM agrees with previous reports.\(^1\)\(^1\)\(^0\)

The bimodal distribution expression of the IRG in ISM-Low and ISM-High patients with SLE is a distinct feature of this biomarker. High-ISM patients with SLE had markedly elevated IRG expression, while patients in the ISM-Low subset had a distribution of gene expression that overlapped with the predominantly unimodal ISM measured in healthy subjects, despite the presence of active disease. The relative distribution of patients who are ISM-High or ISM-Low varied, in part, with disease activity based on BILAG or SELENA-SLEDAI measures, but this appears to be a consequence of the ISM status within each trial and study. Thus, ISM status across SLE trial populations varied from an incidence of ∼50% ISM-High scores in a mild disease population in a Phase I study\(^1\)\(^6\) to ∼75% in moderate-to-severe SLE disease populations in Phase II/III studies that represent patients with ERL and LN.

Despite an apparently increased incidence of ISM-High patients in Phase II/III trials in populations with moderate-to-severe disease activity compared with Phase I studies in populations with mild disease activity, the ISM status within each trial’s cohorts did not correlate with differences in disease activity. Our observations are based on the consistent use of a platform—the qPCR-based ISM—across different trial populations, in contrast to reports of IS associations with increased SLE disease activity based on differing methods applied across different cohorts to measure the IS.\(^1\)\(^0\)\(^1\)\(^6\) For example, in the Phase II ROSE study with patients with moderate-to-severe SLE, ISM status did not correlate with differences in mean measures of disease activity assessed by BILAG or SELENA-SLEDAI.\(^1\)\(^9\)

Further, the skewed incidence of ISM-High patients in moderate-to-severe disease was fairly similar in the ERL and LN populations, indicating that the ISM distribution is not broadly specific with end-organ activity in most patients with SLE. In the EXPLORER\(^1\)\(^7\) and ROSE\(^1\)\(^9\) studies, we did not observe consistent correlations between mucocutaneous disease manifestations and ISM status, and we observed only a modest trend in elevated musculoskeletal disease manifestations in ISM-Low compared with ISM-High patients across the four trials. Of note, we did observe increased CLASI damage scores, but not CLASI activity scores, in the ROSE trial where this instrument was used that suggests the possibility of an association of the ISM biomarker with aspects of cutaneous disease. We also observed a trend for elevated FACIT fatigue scores in ISM-High patients in the ROSE trial. The possibility still remains, however, that there are distinct clinical SLE pathotypes within the ISM subsets that have not yet been identified. We did observe that the ISM-High subset was slightly younger overall across the trials and, in at least the ERL populations, had a lower frequency of white patients, consistent with previous observations.\(^1\)\(^0\)

ISM status does correlate with serological differences between the two subpopulations across multiple trial cohorts with extrarenal SLE. The presence of characteristic SLE autoantibodies, hypocomplementaemia, cytokine production and serum IFN bioactivity varied between ISM-High and ISM-Low patients with lupus. These findings are consistent with previous reports\(^1\)\(^0\)\(^1\)\(^6\) and underscore the role of type I IFNs in systemic immune activation, including extrafollicular differentiation of autoreactive B cells to antibody-secreting plasmablasts via regulation of toll-like receptors (TLRs) and increased survival via BAFF-induced signalling.\(^6\) Thus, the ISM could be a biomarker of systemic immune activation that comanifests with serological abnormalities. Indeed, our multivariate analysis confirmed independent association of ISM magnitude with T cell counts, autoantibodies, cytokine levels and disease duration parameters.

We found no significant differences between the ISM-Low and ISM-High subpopulations in autoantibody presence or titre in patients with LN, and observed
comparable levels of hypocomplementaemia in these subpopulations. So, although immune-serology differences exist between ISM-High and ISM-Low patients with ERL, additional drivers of the IS likely exist in patients with LN, giving rise to a bimodal ISM distribution. This suggests that the regulation of the IRGs could be due in part to an amplification loop where, upon reaching a threshold, genes could be upregulated by additional upstream signals. These signals may include, but are not limited to, nucleic acid-containing IC activation of endosomal TLR7 and TLR9 nucleic acid sensors or activation of cytosolic nucleic acid sensors such as the retinoic acid-inducible gene I-like receptors, nucleotide oligomerisation domain-like receptors, and cyclic GMP-AMP synthase, which lead to type I IFN expression.

Although our analysis was not designed to address the stability of the ISM on a particular background of immunosuppressants, it appears that the most frequently used immunosuppressants (ie, hydroxychloroquine and oral corticosteroids) in lupus management do not significantly impact the ISM status of patients with SLE. In contrast, others have shown that high-dose, pulse intravenous corticosteroids markedly and transiently attenuate the IS in patients with SLE. Further, blockade of IFN-α with rontalizumab in patients with ERL only leads to a partial reduction in ISM score by 2–4 weeks of treatment. This is consistent with observations in patients with SLE treated with a different anti-IFN-α antibody, sifalimumab.

One potential contributing factor to this partial ISM decrease could include suboptimal dosing of patients with anti-IFN-α antibodies, and treatment of patients with higher amounts of this therapy could result in a greater magnitude of decrease of the ISM score. It is also important to consider the complexity of the genome-wide gene expression profile, and the potential limitations of our approach to derive a simplified biomarker that integrates the magnitude of a large number of genes. Indeed, a recent study using modular transcriptional analysis has demonstrated that different a priori-defined IFN-inducible modules have differential associations with disease activity such as SELENA-SLEDAI scores, serology and presence of flare. Further, the different IFN-inducible modules had varying degrees of longitudinal stability, and likely reflected differential contributions of IFN-β and IFN-γ in addition to IFN-α. Clearly, therefore, the IS in patients with SLE is driven by factors beyond IFN-α signalling and may include overlapping Jak-Stat signalling mechanisms used by other cytokines and/or sustained IC derived from pre-existing plasma cells. In this regard, it has recently been reported that blockade of the Lymphotoxin/LIGHT pathway using baminercept, a lymphotoxin-β receptor-immunoglobulin fusion protein, reduced the IS signature in the blood of patients with rheumatoid arthritis with elevated baseline signatures suggesting a role of the Lymphotoxin/LIGHT pathway as an upstream modulator of IFNs in RA and potentially SLE. Furthermore in this study, patients with RA and SLE had lymphopenia associated with elevation of blood IFN signature, and treatment of patients with RA with baminercept subsequently increased lymphocyte counts. Consistent with this observation, it was noteworthy that the ISM-High patients within the trials examined in this study also had reduced circulating leukocyte counts including lymphocytes, monocytes, neutrophils and eosinophils as compared with ISM-Low patients. These data are consistent with a role for IFN signalling in retaining immune cells in tissues during inflammatory disease and therefore contributing to lymphopenia. Additional mechanistic studies are warranted to investigate upstream signals that can specifically induce genes also induced by type I IFNs.

In conclusion, we have characterised the ISM as a surrogate of the peripheral blood global IS, first identified in patients with SLE. The method identifies distinct ISM-Low and ISM-High SLE populations, and has the potential to provide a useful approach to identify and stratify the heterogeneous SLE population in the context of randomised control clinical trials and clinical practice. The correlation of baseline ISM status and clinical response has recently been evaluated in the ROSE Phase II randomised, controlled trial of the safety and efficacy of rontalizumab in extrarenal lupus.

Author affiliations
1Departments of Early Clinical Development, Genentech, South San Francisco, California, USA
2Department of Biostatistics, Genentech, South San Francisco, California, USA
3Department of ITGR Diagnostics Discovery, Genentech, South San Francisco, California, USA
4Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, California, USA
5Department of Pharmacodynamic Biomarkers ITGR, Genentech, South San Francisco, California, USA
6Department of Bioanalytical Sciences, Genentech, South San Francisco, California, USA
7Department of Late Stage Immunology Product Development, Genentech, South San Francisco, California, USA
8Department of Medicine, University of Michigan and the Ann Arbor VA Hospital, Ann Arbor, Michigan, USA
9Department of Pharmacodynamic Biomarkers ITGR, Genentech, South San Francisco, California, USA

Acknowledgements The authors thank Rachel Brock and Sushma Yarlagadda for assistance in processing patient samples from the Michigan SLE cohort, Lauren Nguyen and Zachary Martinez for immunosassay analysis of patient serum samples, and Dr Jane Grogan for scientific discussion of the data. Writing assistance was provided by Genentech.

Contributors All authors made substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content; and final approval of the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding This study was financially supported by Genentech, a member of the Roche Group.

Competing interests WPK, RM, KW, WT, ARA, CC, AM, JMM, PB, JCD, TWB, and MJT: Employees and shareholders of Roche. BCR: Research support from Genentech. All of the authors with the exception of BCR are current or former employees of Genentech, a member of the Roche group.
REFERENCES

1. Koffler D, Agnello V, Thoburn R, et al. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 1971;134:169s–79s.
2. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560–6.
3. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis—the emerging mechanisms. Autoimmun Rev 2008;7:317–21.
4. Strand V, Chu AD. Measuring outcomes in systemic lupus erythematosus clinical trials. Exp Rev Pharmacoecon Outcomes Res 2011;11:455–68.
5. Wollaston SJ, Farewell VT, Isenberg DA, et al. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheum 2004;31:2390–4.
6. Ronnblom L, Eloranta ML, Alm GV. The type I interferon signature in autoimmune diseases. Curr Opin Rheum 2013;25:248–53.
7. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus. Curr Opin Immun 2012;24:530–7.
8. Crow MK. Type I interferon in organ-targeted autoimmunity and inflammatory diseases. Arth Res Ther 2010;12(Suppl 1):S5.
9. Bronson PG, Chaivorapol C, Ortmann W, et al. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immun 2012;24:530–7.
10. Baechler EC, Batiwalla FM, Karpis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Nat Acad Sci 2003;100:2610–5.
11. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711–23.
12. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029–36.
13. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408–20.
14. Lichtman EJ, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus—focus on targeting interferon-alpha. Clin Immunol 2012;143:210–21.
15. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:3866–76.
16. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontuzumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3866–76.
17. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2012;64:222–33.
18. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709–16.
19. Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontuzumab (rhuMab interferon-α) in systemic lupus erythematosus patients (ROSE). Ann Rheum Dis 2015. doi: 10.1136/annrheumdis-2014-206090.
20. Bourgon R, Genteman R, Huber W. Independent filtering increases detection power for high-throughput experiments. Proc Natl Acad Sci 2010;107:95–101.
21. Ronn T, Matikainen S, Lehtonen A, et al. The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promotor analysis of the antiviral Mxα gene. J Interferon Cytokine Res 1998;18:773–81.
22. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001;194:F59–63.
23. Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2013;123:786–91.
24. Guiducci C, Gong M, Xu Z, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339:786–91.
25. Guidduci C, Gong M, Xu Z, et al. The genetics of type I interferon sensitivity in systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2011;63:2407–15.
26. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. J Exp Med 2001;194:F59–63.
27. Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339:786–91.
28. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709–16.
29. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2012;64:222–33.
30. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709–16.

Kennedy WP, Maciuca R, Wolslegel K, et al. Lupus Science & Medicine 2015;2:e00080. doi:10.1136/lupus-2014-00080